XomaXOMA
About: XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Employees: 13
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
1% more capital invested
Capital invested by funds: $203M [Q3] → $205M (+$1.55M) [Q4]
0.55% more ownership
Funds ownership: 65.78% [Q3] → 66.33% (+0.55%) [Q4]
3% less funds holding
Funds holding: 67 [Q3] → 65 (-2) [Q4]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
53% less call options, than puts
Call options by funds: $32K | Put options by funds: $68K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Joseph Pantginis 18% 1-year accuracy 73 / 417 met price target | 435%upside $104 | Buy Reiterated | 28 Mar 2025 |
Financial journalist opinion
Based on 3 articles about XOMA published over the past 30 days
